ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01416402
Recruitment Status : Completed
First Posted : August 15, 2011
Last Update Posted : April 3, 2015
Sponsor:
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.

August 11, 2011
August 15, 2011
April 3, 2015
August 2011
October 2011   (Final data collection date for primary outcome measure)
Proportion of patients achieving sUA <6.0 mg/dL, <5.0 mg/dL, <4.0 mg/dL and <3.0 mg/dL at the end of combination treatment period with each of the doses of arhalofenate [ Time Frame: 36 days ]
Same as current
Complete list of historical versions of study NCT01416402 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Open Label Safety/Efficacy Study of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Gout Patients
A Phase 2, Open-label Study to Evaluate the Safety and Efficacy of Arhalofenate (MBX-102) in Combination With Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
The purpose of this study is to determine whether arhalofenate is safe and effective when dosed in combination with febuxostat in lowering serum uric acid in patients with gout.
Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Hyperuricemia
  • Gout
  • Drug: Arhalofenate
    400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks
    Other Name: MBX-102
  • Drug: Febuxostat
    80 mg once daily orally for 5 weeks
    Other Name: Uloric
  • Drug: Colchicine
    Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
    Other Name: Colcrys
Arhalofenate with febuxostat and colchicine
Interventions:
  • Drug: Arhalofenate
  • Drug: Febuxostat
  • Drug: Colchicine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
27
15
October 2011
October 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Known gout patient (per criteria of the American Rheumatism Association for the classification of the acute arthritis of primary gout in Appendix 3) with a serum uric acid value of at least 8.0 mg/dL at Screening Visit. Patients on allopurinol must agree to discontinue their existing therapy at Visit 1 through the entire duration of the study and must have a sUA value of at least 8.0 mg/dL after a minimum 2 week wash-out at Visit 2.
  2. Male or female, 18-75 years of age at Screening Visit
  3. All female patients must be surgically sterile or post-menopausal (at least 45 years of age with no history of menses for at least 2 years; or any age with no history of menses for at least 6 months and serum FSH ≥ 40 mIU/mL) or must agree to use two medically accepted methods of contraception including a barrier method (see the list in Appendix 4) for the entire duration of the study unless report of complete sexual abstinence.
  4. Female patients must not be pregnant or lactating
  5. Male patients with a female partner of child-bearing potential must agree to use condom or the partner must use a medically acceptable method of contraception for the entire duration of the study.
  6. Estimated CrCl ≥ 50 mL/min as calculated by the by Cockcroft-Gault method
  7. Serum creatinine value must be ≤ 1.3 mg/dL in females and ≤ 1.4 mg/dL in males
  8. Patients must have liver function tests (LFTs) ≤ 1.5X ULN for AST, ALT and T-bilirubin, ≤ 2X ULN for ALP, ≤ 3X ULN for GGT; CK ≤ 3X ULN
  9. All other clinical laboratory parameters must be within normal limits or considered not clinically significant
  10. Electrocardiogram (ECG) must be normal, or if abnormal, considered not clinically significant
  11. Patients must have a systolic blood pressure ≤ 160 mm Hg and a diastolic blood pressure ≤ 95 mm Hg; known hypertensive patients controlled with medication other than diuretics (BP reading as above) may be included
  12. Patients must agree to remain in-clinic for 37 days consecutively and agree to follow the study procedures as described in the protocol

Exclusion Criteria:

  1. Treatment with any ULT other than allopurinol (e.g., probenecid, benzbromarone, febuxostat, or pegloticase) within two weeks of the Screening Visit
  2. Known or suspected secondary hyperuricemia (e.g. due to myeloproliferative disorder, or organ transplant).
  3. Diagnosis of xanthinuria
  4. History of documented or suspected kidney stones
  5. Known infection with the human immunodeficiency virus (HIV) or history of viral hepatitis type B or C
  6. History of illicit drug or alcohol abuse within one year of Screening Visit
  7. History of significant pulmonary disease, upper gastrointestinal (GI) bleeding, documented peptic ulcer disease (unless known H. pylori infection treated successfully without recurrence), or nephrotic syndrome within three years of Screening Visit
  8. History of stroke, TIA, acute myocardial infarction (MI), congestive heart failure (CHF) (NYHA Class II-IV), angina pectoris, coronary intervention procedure (including but not limited to angioplasty, stent placement, coronary revascularization), lower extremity bypass procedure, systemic or intracoronary fibrinolytic therapy within 5 years of screening
  9. Malignancy within five years of Screening Visit (except successfully treated basal cell carcinoma)
  10. Body mass index (BMI) > 42 kg/m2
  11. Current or expected requirement for anticoagulant therapy [except for low-dose (≤ 325 mg/day) aspirin and/or Plavix® 75 mg/day]
  12. Rheumatoid arthritis or other autoimmune disease requiring ongoing treatment
  13. Current or expected treatment with potent CYP3A4 inhibitors (See Appendix 6), cytotoxic agents (azathioprine, mercaptopurine, cyclosporine, cyclophosphamide, etc.), ranolazine, digoxin, theophyline, desipramine, sulphonylurea, thiazolidinedione, diuretics, atypical antipsychotic agents, or phenytoin
  14. Chronic treatment with non-steroidal anti-inflammatory drugs (NSAIDs use to treat acute gout flares is permitted)
  15. Current or expected treatment with systemic corticosteroids (except topical, ophthalmic, intra-articular, or inhaled at a dose < 1600 μg/day) other than to treat acute gout flares
  16. Known hypersensitivity to colchicine or febuxostat
  17. Treatment with any other investigational therapy within the 30 days prior to the Screening Visit, or patients who received at least one dose of blinded study medication while enrolled in any previous arhalofenate trial
  18. Any other condition that compromises the ability of the patient to provide informed consent or to comply with the objectives and procedures of this protocol, as judged by the investigator and/or medical monitor
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01416402
M102-21124
No
Not Provided
Not Provided
CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc.
Not Provided
Not Provided
CymaBay Therapeutics, Inc.
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP